NCT00423202已完成3 期
Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 186
- 主要终点
- Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.
研究概览
简要总结
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age and older
- •Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit
- •Right heart catheterization, completed prior to Screening Visit must meet pre-specified hemodynamic criteria
- •Female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
- •Male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form
排除标准
- •PAH due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea
- •Portopulmonary hypertension
- •Bosentan within four weeks prior to Screening
- •Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks prior to Screening
- •IV inotrope use within two weeks prior to Screening
- •ALT or AST lab value that is greater than 1.5 times the upper limit of normal
- •Pulmonary function tests not meeting pre-specified criteria
- •Contraindication to treatment with an ERA
- •History of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years
- •Females who are pregnant or breastfeeding
结局指标
主要结局
Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.
次要结局
- Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index immediately following exercise, WHO functional class and SF-36 Health Survey.
- Clinical worsening of PAH.
- Assessment of the safety and tolerability of the study drug.
研究者
相似试验
已完成
3 期
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.Pulmonary Arterial HypertensionNCT00423748Gilead Sciences186
进行中（未招募）
1 期
Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension - ARIES-1Pulmonary Arterial HypertensionEUCTR2005-000812-29-HUMyogen, Inc.
已完成
3 期
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary HypertensionPulmonary HypertensionNCT00380068Gilead Sciences224
进行中（未招募）
不适用
ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1Pulmonary Arterial HypertensionEUCTR2005-000812-29-DEMyogen, Inc186
进行中（未招募）
不适用
ARIES-1 Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension” - ARIES-1Pulmonary Arterial HypertensionEUCTR2005-000812-29-BEMyogen, Inc186